Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Diabetes Rev ; 16(2): 117-136, 2020.
Article in English | MEDLINE | ID: mdl-31237215

ABSTRACT

BACKGROUND: Among the millions of people around the world, the most prevalent metabolic disorder is diabetes mellitus. Due to the drawbacks which are associated with commercially available antidiabetic agents, new therapeutic approaches are needed to be considered. Alpha-amylase is a membrane- bound enzyme which is responsible for the breakdown of polysaccharides such as starch to monosaccharides which can be absorbed. METHODS: We searched the scientific database using alpha-amylase, diabetes, antidiabetic agents as the keywords. Here in, only peer-reviewed research articles were collected which were useful to our current work. RESULTS: To overcome the research gap, the alpha-amylase enzyme is regarded as a good target for antidiabetic agents to design the drug and provide an alternate approach for the treatment of type 2 diabetes mellitus. Basically, alpha-amylase inhibitors are classified into two groups: proteinaceous inhibitors, and non-proteinaceous inhibitors. Recently, non-proteinaceous inhibitors are being explored which includes chalcones, flavones, benzothiazoles, etc. as the potential antidiabetic agents. CONCLUSION: Herein, we discuss various potential antidiabetic agents which are strategically targeted alpha-amylase enzyme. These are having lesser side effects as compared to other antidiabetic agents, and are proposed to prevent the digestion and absorption of glucose leading to a decrease in the blood glucose level.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Enzyme Inhibitors/therapeutic use , Hypoglycemic Agents/therapeutic use , alpha-Amylases/antagonists & inhibitors , Blood Glucose/metabolism , Humans
2.
Bioorg Chem ; 82: 156-162, 2019 02.
Article in English | MEDLINE | ID: mdl-30321778

ABSTRACT

Diabetes is the most prevalent metabolic disorder causing a high rate of mortality and morbidity. Recently alpha-amylase is reported to be good drug design target for the treatment of diabetes mellitus. We have designed 116 molecules based on aza-Michael adduct of trans-chalcone as 1,3 diaryl-3-(arylamino)propan-1-ones which were studied by molecular docking and among them best six derivatives were synthesized easily via aza-Michael addition on trans-chalcone using KOH as a catalyst and evaluated for alpha-amylase inhibition along with antioxidant activity. It was observed that all compounds have alpha-amylase inhibitory activity but at different extents. The molecule 3e is the most potent alpha-amylase inhibitor of this series. 3a is the second most potent compound, whereas only one molecule 3d has shown antioxidant activity.


Subject(s)
Aniline Compounds/chemistry , Antioxidants/chemistry , Glycoside Hydrolase Inhibitors/chemistry , Propiophenones/chemistry , alpha-Amylases/antagonists & inhibitors , Aniline Compounds/chemical synthesis , Antioxidants/chemical synthesis , Drug Design , Glycoside Hydrolase Inhibitors/chemical synthesis , Humans , Molecular Docking Simulation , Propiophenones/chemical synthesis , alpha-Amylases/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...